TY - JOUR
T1 - The Harmonizing Outcome Measures for Eczema (HOME) Roadmap
T2 - A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology
AU - Schmitt, Jochen
AU - Apfelbacher, Christian
AU - Spuls, Phyllis I.
AU - Thomas, Kim S.
AU - Simpson, Eric L.
AU - Furue, Masutaka
AU - Chalmers, Joanne
AU - Williams, Hywel C.
N1 - Funding Information:
This publication describes work conducted on behalf of the Harmonizing Outcome Measures for Atopic dermatitis (HOME) initiative that is supported through an independent research grant funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0407-10177). Support for Simpson was made possible with funding from a Mentored Patient-Oriented Research Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (5K23AR057486).
Publisher Copyright:
© 2015 The Society for Investigative Dermatology.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Core outcome sets (COSs) are consensus-derived minimum sets of outcomes to be assessed in a specific situation. COSs are being increasingly developed to limit outcome-reporting bias, allow comparisons across trials, and strengthen clinical decision making. Despite the increasing interest in outcomes research, methods to develop COSs have not yet been standardized. The aim of this paper is to present the Harmonizing Outcomes Measures for Eczema (HOME) roadmap for the development and implementation of COSs, which was developed on the basis of our experience in the standardization of outcome measurements for atopic eczema. Following the establishment of a panel representing all relevant stakeholders and a research team experienced in outcomes research, the scope and setting of the core set should be defined. The next steps are the definition of a core set of outcome domains such as symptoms or quality of life, followed by the identification or development and validation of appropriate outcome measurement instruments to measure these core domains. Finally, the consented COS needs to be disseminated, implemented, and reviewed. We believe that the HOME roadmap is a useful methodological framework to develop COSs in dermatology, with the ultimate goal of better decision making and promoting patient-centered health care.
AB - Core outcome sets (COSs) are consensus-derived minimum sets of outcomes to be assessed in a specific situation. COSs are being increasingly developed to limit outcome-reporting bias, allow comparisons across trials, and strengthen clinical decision making. Despite the increasing interest in outcomes research, methods to develop COSs have not yet been standardized. The aim of this paper is to present the Harmonizing Outcomes Measures for Eczema (HOME) roadmap for the development and implementation of COSs, which was developed on the basis of our experience in the standardization of outcome measurements for atopic eczema. Following the establishment of a panel representing all relevant stakeholders and a research team experienced in outcomes research, the scope and setting of the core set should be defined. The next steps are the definition of a core set of outcome domains such as symptoms or quality of life, followed by the identification or development and validation of appropriate outcome measurement instruments to measure these core domains. Finally, the consented COS needs to be disseminated, implemented, and reviewed. We believe that the HOME roadmap is a useful methodological framework to develop COSs in dermatology, with the ultimate goal of better decision making and promoting patient-centered health care.
UR - http://www.scopus.com/inward/record.url?scp=84925857771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925857771&partnerID=8YFLogxK
U2 - 10.1038/jid.2014.320
DO - 10.1038/jid.2014.320
M3 - Article
C2 - 25186228
AN - SCOPUS:84925857771
SN - 0022-202X
VL - 135
SP - 24
EP - 30
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 1
ER -